Volume 387, Issue 10022, Pages 945-956 (March 2016) Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial Prof Ian J Jacobs, FRCOG, Prof Usha Menon, FRCOG, Andy Ryan, PhD, Aleksandra Gentry-Maharaj, PhD, Matthew Burnell, PhD, Jatinderpal K Kalsi, PhD, Prof Nazar N Amso, PhD, Sophia Apostolidou, PhD, Elizabeth Benjamin, FRCPath, Derek Cruickshank, FRCOG, Danielle N Crump, BSN, Susan K Davies, RGN, Anne Dawnay, PhD, Stephen Dobbs, FRCOG, Gwendolen Fletcher, DCR(R), Jeremy Ford, MSc, Keith Godfrey, FRCOG, Richard Gunu, MSc, Mariam Habib, PhD, Rachel Hallett, PhD, Jonathan Herod, MRCOG, Howard Jenkins, FRCOG, Chloe Karpinskyj, BSc, Simon Leeson, FRCOG, Sara J Lewis, MSc, William R Liston, Alberto Lopes, FRCOG, Tim Mould, FRCOG, John Murdoch, FRCOG, David Oram, FRCOG, Dustin J Rabideau, MSc, Karina Reynolds, FRCOG, Ian Scott, FRCOG, Mourad W Seif, FRCOG, Aarti Sharma, PhD, Naveena Singh, FRCPath, Julie Taylor, MSc, Fiona Warburton, MSc, Prof Martin Widschwendter, Karin Williamson, FRCOG, Robert Woolas, MD, Prof Lesley Fallowfield, DPhil, Prof Alistair J McGuire, PhD, Prof Stuart Campbell, DSc, Prof Mahesh Parmar, DPhil, Steven J Skates, PhD The Lancet Volume 387, Issue 10022, Pages 945-956 (March 2016) DOI: 10.1016/S0140-6736(15)01224-6 Copyright © 2016 Jacobs Menon et al. Open Access article published under the terms of CC BY Terms and Conditions
Figure 1 Trial profile MMS=multimodal screening. USS=ultrasound screening. *Events occurred before recruitment, but discovered after randomisation. The Lancet 2016 387, 945-956DOI: (10.1016/S0140-6736(15)01224-6) Copyright © 2016 Jacobs Menon et al. Open Access article published under the terms of CC BY Terms and Conditions
Figure 2 (A) Cumulative ovarian cancer and (B) ovarian and peritoneal cancer deaths The Royston-Parmar model is shown in the appendix (p 12, 13). HR=hazard ratio. MMS=multimodal screening. USS=ultrasound screening. The Lancet 2016 387, 945-956DOI: (10.1016/S0140-6736(15)01224-6) Copyright © 2016 Jacobs Menon et al. Open Access article published under the terms of CC BY Terms and Conditions
Figure 3 Rates of ovarian cancer The figure including confidence limits is in the appendix (p 14). MMS=multimodal screening. USS=ultrasound screening. The Lancet 2016 387, 945-956DOI: (10.1016/S0140-6736(15)01224-6) Copyright © 2016 Jacobs Menon et al. Open Access article published under the terms of CC BY Terms and Conditions
Figure 4 (A) Cumulative ovarian cancer and (B) ovarian and peritoneal deaths in MMS and no screening groups after exclusion of prevalent cases HRs and mortality reductions for 0–7 years and 7–14 years calculated from the Royston-Parmar model. Cumulative mortality curves from the Royston-Parmar model are overlaid onto Kaplan-Meier curves. HR=hazard ratio. MMS=multimodal screening. The Lancet 2016 387, 945-956DOI: (10.1016/S0140-6736(15)01224-6) Copyright © 2016 Jacobs Menon et al. Open Access article published under the terms of CC BY Terms and Conditions